Summit Wealth Group LLC Buys Shares of 40,000 Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Summit Wealth Group LLC acquired a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 40,000 shares of the biopharmaceutical company’s stock, valued at approximately $66,000.

Several other institutional investors have also recently modified their holdings of ESPR. Bellevue Group AG lifted its stake in shares of Esperion Therapeutics by 136.5% during the first quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock worth $26,650,000 after purchasing an additional 5,739,800 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Esperion Therapeutics by 71.8% in the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock valued at $23,655,000 after acquiring an additional 3,688,796 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Esperion Therapeutics by 94.2% in the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after purchasing an additional 2,087,635 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Esperion Therapeutics by 3,278.3% during the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock valued at $1,271,000 after buying an additional 555,382 shares in the last quarter. Finally, Inspire Investing LLC acquired a new position in shares of Esperion Therapeutics in the second quarter worth $758,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Needham & Company LLC reduced their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Finally, HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Esperion Therapeutics currently has an average rating of “Hold” and an average target price of $8.17.

Esperion Therapeutics Stock Up 1.4 %

ESPR opened at $2.15 on Tuesday. The firm has a market capitalization of $423.64 million, a P/E ratio of -3.36 and a beta of 0.96. Esperion Therapeutics, Inc. has a 12-month low of $1.15 and a 12-month high of $3.40. The stock’s 50 day moving average price is $1.97 and its two-hundred day moving average price is $2.14.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.